Quick Comparison

KlothoPentosan Polysulfate
Half-LifeRecombinant alpha-Klotho: approximately 10-15 hours (estimated from primate studies)20-27 hours
Typical DosageCurrently no established human therapeutic dose. Phase 1 clinical trials of recombinant alpha-Klotho are exploring intravenous and subcutaneous dose-escalation protocols. Animal studies have used 10-50 mcg/kg subcutaneous several times per week.Oral (Elmiron): 100 mg three times daily for interstitial cystitis. Injectable (compounding): 2-3 mg/kg subcutaneous or intramuscular once or twice weekly for 4-8 weeks for joint applications.
AdministrationRecombinant alpha-Klotho: subcutaneous or intravenous injection (clinical trial settings only)Oral capsule or subcutaneous/intramuscular injection
Research Papers5 papers11 papers
Categories

Mechanism of Action

Klotho

Klotho is a single-pass transmembrane protein primarily expressed in the kidney, parathyroid gland, and choroid plexus, with a soluble form (s-Klotho) cleaved from the membrane and circulating systemically as an endocrine factor. It exists in three forms — alpha-Klotho (the most studied, anti-ageing form), beta-Klotho (which partners with FGF21), and gamma-Klotho — each with distinct receptor partnerships and tissue effects.

At the receptor level, alpha-Klotho is the obligate co-receptor for fibroblast growth factor 23 (FGF23), enabling FGF23 to bind and activate FGFR1 receptors in the kidney to regulate phosphate excretion. This makes Klotho a central node in mineral metabolism. Beyond this canonical role, soluble Klotho exerts numerous endocrine effects: it inhibits the IGF-1/insulin signalling pathway (a conserved longevity mechanism shared with caloric restriction), enhances expression of antioxidant enzymes via FoxO transcription factor activation, suppresses Wnt signalling (reducing stem cell exhaustion), inhibits TGF-beta signalling (preventing fibrosis), and blocks NF-kB and NLRP3 inflammasome activation (reducing inflammaging).

The ageing phenotype connection is striking: mice lacking Klotho develop multi-organ ageing — atherosclerosis, osteoporosis, skin atrophy, cognitive decline — within weeks of birth, while mice with elevated Klotho expression live up to 30% longer than controls. In humans, circulating Klotho levels decline with age, and lower levels associate with increased mortality and chronic disease risk in observational studies. Recombinant alpha-Klotho is in early clinical development as a potential therapy for chronic kidney disease, cognitive decline, and broader age-related diseases. The 2026 research wave around Klotho has positioned it as one of the most promising single-protein interventions in the longevity field, though no therapeutic Klotho product is yet approved for human use.

Pentosan Polysulfate

Pentosan Polysulfate (PPS) is a semi-synthetic, sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its structure consists of a xylose backbone with sulfate ester groups at positions 2 and 3, giving it a high negative charge density similar to heparin and endogenous glycosaminoglycans like heparan sulfate. This polyanionic character is central to its multiple mechanisms of action.

In joint and cartilage repair, PPS stimulates chondrocyte proteoglycan synthesis — the production of aggrecan and other proteoglycans that form the hydrated gel matrix of articular cartilage. Proteoglycans are responsible for cartilage's compressive resilience and water retention, and their loss is a hallmark of osteoarthritis. PPS also inhibits matrix metalloproteinases (MMPs), particularly MMP-3, MMP-9, and MMP-13, which are the enzymes responsible for cartilage matrix degradation in osteoarthritis. By simultaneously promoting matrix synthesis and inhibiting matrix breakdown, PPS shifts the balance toward cartilage repair. Additionally, PPS improves synovial fluid viscosity by stimulating hyaluronic acid synthesis from synoviocytes, partially restoring the lubrication and shock-absorbing properties lost in arthritic joints.

PPS has several additional pharmacological properties. It inhibits complement activation (particularly the alternative pathway), reducing inflammatory damage to joint tissues. It has fibrinolytic activity — promoting the dissolution of fibrin deposits that can form in inflamed synovial tissue and contribute to joint adhesions. It inhibits certain lipases and has lipid-clearing properties. In its FDA-approved indication (interstitial cystitis), PPS is thought to replenish the damaged glycosaminoglycan layer lining the bladder epithelium, restoring the protective barrier against urine irritants. The recent FDA warning about retinal pigmentary maculopathy with long-term oral use (affecting approximately 1 in 4 long-term users) appears to be related to accumulation of PPS metabolites in the retinal pigment epithelium, where they may disrupt lysosomal function and pigment recycling.

Risks & Safety

Klotho

Common

limited human safety data. Animal studies show generally good tolerability.

Serious

theoretical risk of altering phosphate and calcium homeostasis (Klotho is a critical regulator of FGF23 signalling); unknown effects on cancer biology in long-term use.

Rare

allergic reactions to recombinant protein. Quality and authenticity of any product sold as Klotho outside formal clinical trials should be considered highly uncertain.

Pentosan Polysulfate

Common

bruising, injection site pain, headache, nausea, diarrhea, hair loss (oral).

Serious

retinal pigmentary maculopathy with long-term oral use (FDA warning — unique, potentially irreversible vision damage), liver damage (rare).

Rare

low platelet count, severe allergic reactions. Regular eye exams recommended with oral use beyond 2 years.

Full Profiles